Indication
CD30-positive mycosis fungoides
CD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes. Read more about CD30-positive mycosis fungoides
2 drugs 2 manufacturers
Drugs that treat it
Common CD30-positive mycosis fungoides therapies.
ADCETRIS (brentuximab vedotin)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes.
It primarily targets the skin in adult populations and may manifest across disease stages as persistent patches, indurated plaques, or cutaneous tumors, often arising during large-cell transformation or in advanced progression.
Pathophysiologically, epidermotropic and dermal malignant helper T cells upregulate this tumor necrosis factor receptor superfamily member, providing a defined biomarker that differentiates it from typical CD30-negative presentations and indicates potential susceptibility to CD30-directed therapies.
- cancer.gov
CD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes It primarily targets the skin in adult populations and may manifest across disease stages as persistent patches, indurated plaques, or cutaneous tumors, often arising during large-cell transformation or in advanced progression Pathophysiologically, epidermotropic and derma...
- turkjdermatol.com
CD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes Pathophysiologically, epidermotropic and dermal malignant helper T cells upregulate this tumor necrosis factor receptor superfamily member, providing a defined biomarker that differentiates it from typical CD30-negative presentations and indicates potential susceptibility ...
- clfoundation.org
It primarily targets the skin in adult populations and may manifest across disease stages as persistent patches, indurated plaques, or cutaneous tumors, often arising during large-cell transformation or in advanced progression
- cancer.gov
It primarily targets the skin in adult populations and may manifest across disease stages as persistent patches, indurated plaques, or cutaneous tumors, often arising during large-cell transformation or in advanced progression
Personalize your experience
Follow CD30-positive mycosis fungoides and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.